[HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
Delaugerre
C
C
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D016903:Drug Monitoring; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors